SCHEMBL5115329

SCHEMBL5115329

Cc1ccc2c(O)c(-c3cc4c(=O)oc5cc(C)ccc5c4o3)c(=O)oc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.44
ESR1 P03372 4/20 0.42
ESR2 Q92731 4/20 0.42
ERAP1 Q9NZ08 1/20 0.42
NOX4 Q9NPH5 1/20 0.42
NQO1 P15559 2/20 0.42
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 3/20 0.41
MAPT P10636 3/20 0.41
KMT2A Q03164 3/20 0.41
CYP3A4 P08684 2/20 0.41
CDC25A P30304 1/20 0.41
CDC25C P30307 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B3 P37058 1/20 0.40
NPC1 O15118 1/20 0.39
VKORC1 Q9BQB6 1/20 0.39
ALDH1A1 P00352 2/20 0.38
GAA P10253 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5125176 0.86 MAOB (0.56) MAOBNQO1KDM4EMEN1MAPT
SCHEMBL5111826 0.86 NOX4 (0.57) ESR1ESR2ERAP1NOX4NQO1
SCHEMBL5120928 0.84 MAOA (0.46) MAOBESR1ESR2NOX4NQO1
SCHEMBL5119152 0.83 NOX4 (0.40) ESR1ESR2ERAP1NOX4NQO1
SCHEMBL5111346 0.83 NQO1 (0.57) MAOBESR2NQO1KDM4EMEN1
SCHEMBL5111292 0.82 KDM4E (0.50) MAOBNQO1KDM4EMEN1MAPT
SCHEMBL5118825 0.81 NQO1 (0.52) MAOBESR1ESR2ERAP1NOX4
SCHEMBL5119551 0.76 NQO1 (0.42) MAOBESR1ESR2ERAP1NQO1
SCHEMBL28156052 0.76 NOX4 (0.62) MAOBESR1ESR2ERAP1NOX4
SCHEMBL5114480 0.76 MAOA (0.40) MAOBERAP1NOX4NQO1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US claimed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US claimed
EP-1648902-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA-ISTRAZIVACKI INSTITUT d.o.o. (HR) 2006-04-26 EP claimed
WO-2005010007-A1 SUBSTITUTED FUROCHROMENES, PREPARATION THEREOF AND THEIR ANTIINFLAMMATORY ACTION PLIVA- ISTRAZIVACKI INSTITUT D.O.O. (HR) 2005-02-03 WO claimed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-7384975-B2 Substituted furochromenes, preparation thereof and their antiinflammatory action GLAXOSMITHKLINE ISTRAZIVACKI CENTAR ZAGREB D.O.O. (HR) 2008-06-10 US disclosed
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) 2006-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060148889-A1 Substituted furochromenes, preparation thereof and their antiinflammatory action CYP11B2, CYP11B1, LTC4S MAOB 322/4885ESR1 1942/4885ESR2 962/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.